AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing Of Claims:

1. (Withdrawn) A composition, comprising one or more polysaccharides and one or more therapeutic agents, wherein said composition enhances therapeutic efficacy and reduces toxicity associated with said therapeutics.

2. (Withdrawn) The composition of claim 1, wherein said polysaccharide is branched or unbranched.

3. (Withdrawn) The composition of claim 1, wherein said polysaccharide is selected from the group consisting of galactomannan, arabinogalactan, rhamnogalacturonan and a combination thereof.

4. (Withdrawn) The composition of claim 3, wherein said galactomannan is a β-1, 4-D-galactomannan.

5. (Withdrawn) The composition of claim 3, wherein said galactomannan is (((1, 4)-linked β-D-mannopyranose)$_{17}$ - ((1, 6)-linked-β-D- galactopyranose)$_{10}$)$_{12}$).

6. (Withdrawn) The composition of claim 5, wherein said (((1, 4)- linked β-D-mannopyranose)$_{17}$ - ((1, 6)-linked-β-D- galactopyranose)$_{10}$)$_{12}$) has a molecular weight ranging from about 2,000 Da to 600,000 Da.

7. (Withdrawn) The composition of claim 5, wherein said (((1,4)- linked β-D-mannopyranose)$_{17}$ - ((1, 6)-linked-β-D- galactopyranose)$_{10}$)$_{12}$) has a molecular weight ranging from about 50,000 Da to 415,000 Da.

8. (Withdrawn) The composition of claim 5, wherein said (((1, 4) linked β-D-mannopyranose)$_{17}$ - ((1, 6)-linked-β-D- galactopyranose)$_{10}$)$_{12}$) has a molecular weight ranging from about 4000 Da to 60,000 Da.

9. (Withdrawn) The composition of claim 1, wherein said therapeutic agent is selected from the group consisting of 5-FU, 5-FUdR, methotrexate, ara-C, 6-mercaptopurine, 6-thioguanine, hydroxyurea, vinblastine, vincristine, vindesine, mechlorethamine, phenylalanine mustard, chlorambucil, ethylenimines, methyl melamines, alkylsulfonates, carmustine, lomustine, streptozocin, cisplatin, dacarbazine, procarbazine, doxorubicin, dactinomycin, mitomycin C, plycamycin, cyclophosphamide, melphalan, thiotepa, busulfan, prednisone, prednisolone, triamcinolone, paclitaxel, and combinations thereof.

10. (Withdrawn) The composition of claim 9, wherein said therapeutic agent is selected from the group consisting of 5-FU, 5-FUdR, cisplatin, and combinations thereof.

11. (Withdrawn) The composition of claim 10, wherein said therapeutic agent is 5-FU.

12. (Withdrawn) The composition of claim 1 further comprising leucovorin.

13. (Currently Amended) A method for improving biodistribution of a chemotherapeutic agent in a body, comprising:

Obtaining an admixture of ~~((1, 4)-linked β-D-mannopyranose)$_{17}$-((1, 6)-linked β-D-galactopyranose)$_{10}$)$_{12}$~~ galactomannan and the chemotherapeutic agent in a pharmaceutically acceptable carrier; and

Nonorally administering to the body an effective amount of the admixture so as to improve biodistribution of the chemotherapeutic agent in the body.

14. (Previously Presented) The method of claim 13, wherein said chemotherapeutic agent is selected from the group consisting of fluoropyramidines ("5-FU"), 5-fluorodeoxyuridine ("5-FUdR"), methotrexate, ara-C, 6-mercaptopurine, 6-thioguanine, hydroxyurea, vinblastine, vincristine, vindesine, mechlorethamine, phenylalanine mustard, chlorambucil, ethylenimines, methyl melamines, alkylsulfonates, carmustine, lomustine, streptozocin, cisplatin, dacarbazine, procarbazine, doxorubicin, dactinomycin, mitomycin C, plycamycin, cyclophosphamide, melphalan, thiotepa, busulfan, prednisone, prednisolone, triamcinolone, paclitaxel, and combinations thereof.

15. (Previously Presented) The method of claim 13, wherein said chemotherapeutic agent is selected from the group consisting of fluoropyramidines ("5-FU"), 5-fluorodeoxyuridine ("5-FUdR"), cisplatin, and combinations thereof.

16. (Canceled)

17. (Currently Amended) The method of claim 13 ~~further comprising~~ wherein said admixture is further comprised of leucovorin.

18. (Canceled)

19. (Currently Amended) The method of claim 13, wherein said admixture has an amount of said galactomannan ~~(((1, 4)- linked β-D-mannopyranose)$_{17}$ – ((1, 6)-linked β-D-galactopyranose)$_{10}$)$_{12}$~~ and an amount of said chemotherapeutic agent in a ratio between about 10:1 to 1:10.

20. (Currently Amended) The method of claim 13, wherein said admixture has an amount of said galactomannan ~~(((1, 4)- linked β-D-mannopyranose)$_{17}$ – ((1, 6)-linked β-D-galactopyranose)$_{10}$)$_{12}$~~ and an amount of said chemotherapeutic agent in a ratio between about 6:1 to 1:3.

21. (Canceled)

22. (Currently Amended) A method for improving the biodistribution of both a chemotherapeutic agent and a proteinous chemotherapeutic agent in a body, comprising:

Obtaining an admixture of galactomannan ~~(((1, 4)- linked β-D-mannopyranose)$_{17}$ – ((1, 6)-linked β-D – galactopyranose)$_{10}$)$_{12}$),~~ the chemotherapeutic agent and ~~a~~ the proteinous chemotherapeutic; and

Nonorally a~~A~~dministering to the body an effective amount of the admixture so as to improve the biodistribution of the chemotherapeutic agent and the proteinous chemotherapeutic agent in the body.

23. (Previously Presented) The method of treatment of claim 22, wherein said proteinous chemotherapeutic is a cytokine.

24. (Previously Presented) The method of treatment of claim 22, wherein said proteinous chemotherapeutic agent is selected from the group consisting of interleukin-2 ("IL-2"), interleukin-12 ("IL-12"), or α-interferon or both.

25. (Previously Presented) The method of treatment of claim 22, wherein said chemotherapeutic agent is selected from the group consisting of fluoropyramidines ("5-FU"), 5-fluorodeoxyuridine ("5-FUdR"), methotrexate, ara-C, 6-mercaptopurine, 6-thioguanine, hydroxyurea, vinblastine, vincristine, vindesine, mechlorethamine, phenylalanine mustard, chlorambucil, ethylenimines, methyl melamines, alkylsulfonates, carmustine, lomustine, streptozocin, cisplatin, dacarbazine, procarbazine, doxorubicin, dactinomycin, mitomycin C, plycamycin, cyclophosphamide, melphalan, thiotepa, busulfan, prednisone, prednisolone, triamcinolone, paclitaxel, and combinations thereof.

26. (Previously Presented) The method of treatment of claim 22, wherein said chemotherapeutic agent is selected from the group consisting of fluoropyramidines ("5-FU"), 5-fluorodeoxyuridine ("5-FUdR"), cisplatin, and combinations thereof.

27. (Previously Presented) The method of treatment of claim 22, wherein said chemotherapeutic agent is a fluoropyramidine ("5-FU").

28. (Currently Amended) The method of treatment of claim 22, wherein said admixture is further comprising of leucovorin.

29. (Currently Amended) A method for improving the biodistribution of a proteinous chemotherapeutic in a body, comprising:

Obtaining an admixture of a proteinous chemotherapeutic and galactomannan ~~((1, 4)-linked β-D-mannopyranose)$_{17}$-((1, 6)-linked-β-D-galactopyranose)$_{10}$)$_{12}$~~ in a pharmaceutically acceptable carrier; and

Nonorally administering to the body an effective amount of the admixture so as to improve the biodistribution of the proteinous chemotherapeutic in the body.

30. (New) The method of claim 29 where said proteinous chemotherapeutic is selected from the group consisting of cytokine, chemokine, interleukin-2 ("IL-2"), interleukin-12 ("IL-12"), α-interferon, immune system messengers or both.

31. (New) The method of claim 13, wherein the molecular weight of the galactomannan is in the range of from about 4kD to about 200 kD.

32. (New) The method of claim 13, wherein the molecular weight of the galactomannan is in the range of from about 40kD to about 60 kD.

33. (New) The method of claim 22, wherein the molecular weight of the galactomannan is in the range of from about 4kD to about 200 kD.

34. (New) The method of claim 22, wherein the molecular weight of the galactomannan is in the range of from about 40kD to about 60 kD.

35. (New) The method of claim 29, wherein the molecular weight of the is in the range of from about 4kD to about 200 kD.

36. (New) The method of claim 13, wherein the molecular weight of the galactomannan is in the range of from about 40kD to about 60 kD.